newsfilter
← Latest News
GlobeNewswire·

Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights

– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in